LAVCA VC
  • News Feed
  • VC Data
  • Directories
  • Features
  • Tech Growth Coalition
  • #changetheratio
  • Engage
    • VC Council
    • VC Members
  • LAVCA
  • Member Login
  • Member Access

LAVCA VC

  • News Feed
  • VC Data
  • Directories
  • Features
  • Tech Growth Coalition
  • #changetheratio
  • Engage
    • VC Council
    • VC Members
  • LAVCA

Valor Capital and DNA Capital Lead a US$11m Series B in Sanar

April 14, 2020
Valor and DNA invest in Sanar

Valor Capital and DNA Capital led a US$11m Series B in Sanar, a Brazilian edtech platform designing customized online training for careers in healthcare, with follow-on from e.bricks Ventures and Vox Capital.

 

(Press Release) São Paulo, April 2020 – Sanar, a Brazilian MedTech that has the largest online medical education platform in the country, closed its series B round with an investment of US$ 11 million (equivalent to $5,21 at the exchange rate of April 14, 2020), co-led by the investment funds DNA Capital and Valor Capital. The round also had the participation of Vox Capital and e.Bricks Ventures, investors of Sanar in Series A. With the new resources, the startup will expand its staff and make massive investments in technology.

Operating 100% online, Sanar plans to be, in four years, the first company to be present throughout the professional journey of doctors and other health professionals. Today, the startup already has customers in more than 5,000 cities and 7 countries such as Argentina, Paraguay, Bolivia and Portugal.

“Our mission is to offer all the tools for doctors to become super doctors. The demand for these professionals is growing and that is why they should be increasingly productive, humane and will need access to quality content and education”, explains Ubiraci Mercês, CEO of Sanar.

According to Antoine Colaco, a partner at Valor Capital Group, the startup can transform health in a disruptive way. “Sanar serves the medical professional at various stages of their careers, providing high quality information and on multiple platforms”.

The startup understands that doctors are the key to making the health system more efficient. “Today, the health system is complex and inefficient, and a large part of the cost chain decisions in this sector are made by this professional. Increasing their capacity can generate unimaginable gains for society”.

To help fulfill this mission, Sanar has built products for every moment of the medical journey. For students, SanarFlix, an education platform with thousands of contents created by the best teachers in the country. For those who want to take the residency exams, there is the Sanar Medical Residency preparatory course. For the day-to-day necessities of doctors, the company created the Yellowbook, an intelligent guidance app that helps in quick and reliable decision making.

Sanar’s strategy also involves creating online communities with free content and interaction between users. Therefore, the company is able to quickly identify the demands of doctors and then built the production of content in line with what they need or even create new products.

It was through this that Sanar identified, for example, that medical students and doctors in training face financial difficulties during this period. Based on this insight, SanarUp was created, offering financing for those who need extra money to continue their studies.

“Sanar is an example of an innovative company that is making a difference by expanding the frontiers of what is possible to be done in health” says Luiz Henrique Noronha, VC director at DNA Capital.

Combining the knowledge generated from data and behavior analysis with technology makes it possible to create solutions at a level much higher than the market. Vinícius Cogo, pediatrician and part of the Sanar team, comments “We are generating an incredible amount of data on the behavior of doctors and cataloging a vast amount of technical knowledge of medicine”.

While advancing in the construction of solutions for each stage of the doctor’s life, Sanar produces and makes knowledge available free of charge through clinical cases, conduct guides, protocols, classes, scientific articles and a multitude of contents.

That way, the company increasingly consolidates itself as the ideal place to search and offer information for medical practice. In the future, the company wants to be able to assist doctors in real-time consultations, helping to read tests and recommend treatment according to the most up-to-date guidelines, especially for those professionals who operate in places with low health care.

“We believe that man and machine combined will produce medicine from another level. We are only at the beginning of this journey”, adds Ubiraci.

Valor Capital and DNA Capital Lead a US$11m Series B in Sanar was last modified: April 15th, 2020 by cramos
. Vinícius CogoBrazilDealsDNA Capitale.BricksHealthtechInvestmentLuiz Henrique NoronhasanarSanarUpUbiraci MercêsValor CapitalVenture CapitalVox CapitalYellowbook
0
Facebook Twitter Google +

Submit VC News

Have private equity or venture capital related news that you would like to share? Submit your press releases and news to news@lavca.org.

Categories

  • Deals
  • Exits
  • Regulatory
  • M&A
  • New Funds & Firms
  • Partnerships

Sector Tags

agribusiness AgTech Artificial Intelligence B2B biotech Consumer/Retail delivery Digital Media & Entertainment e-commerce ecommerce EdTech Education Energy Enterprise Software Financial Services fintech foodtech Healthcare Healthtech HRTECH Human Resources Impact Impact Investing Infrastructure IoT IT logistics Logistics & Distribution logistics and distribution marketplace Marketplaces Mobile Private Capital Private Equity Proptech Real Assets Real Estate SaaS Software Startup startups Technology Telecommunications Transportation venture capital

Geography Tags

Alquilando Argentina Argentine Austria Belize Bolivia Brasil Brazil Canada Canary Caribbean Central America Chile Colombia Costa Rica Dominican Republic Ecuador El Salvador Guatemala Honduras India International INTL Israel Jamaica Japan Kenya LatAm Latin America Mexico Miami Nicaragua Pan-Regional Panama Paraguay Peru Portugal Puerto Rico South Korea Spain United States Uruguay US USA Venezuela
LatAm Venture Bulletin

LatAm Venture Bulletin

The LatAm Venture Bulletin is a must-read roundup of startup deals and news on emerging technologies in Latin America, delivered to over 6,000+ investors, entrepreneurs, and corporates bi-weekly.
Asset Class *

Tweets

  • 🚀READ LAVCA's LatAm Venture Bulletin featuring: #edtech deep dive with @descomplica; #ESG #CaseStudy featuring Cana… https://t.co/jFFMxVRpcn

    25-Feb-2021

    Reply Retweet Favorite
  • LAVCA recently spoke with Maria Pia Iannariello, Co-Founder & COO at @mgminnovagroup, about the opportunity for pri… https://t.co/i7XUo807Kl

    16-Feb-2021

    Reply Retweet Favorite
  • ☑️SIGN UP for the #LATAM Private Capital Update: this week featuring @L_Catterton Exits Espaçolaser; Vinci in… https://t.co/ag2JqwwOOS

    10-Feb-2021

    Reply Retweet Favorite
  • READ LAVCA’s latest deal case featuring @PC_Capital investment in 🇲🇽 agribusiness/retail seeds company Rancho los… https://t.co/R7ChIFYyGq

    03-Feb-2021

    Reply Retweet Favorite
  • 📢Exciting news to kick off 2021: Nicolás Szekasy of @KaszekVentures was appointed LAVCA Board Chair; Juan Alberto L… https://t.co/k6xlZQ0GKi

    21-Jan-2021

    Reply Retweet Favorite

Keep in touch

Twitter Linkedin Youtube

About LAVCA

 

LAVCA is the Association for Private Capital Investment in Latin America, a not-for-profit membership organization dedicated to supporting the growth of private capital in Latin America and the Caribbean through research, education, networking and advocacy.

LAVCA Offices

    New York City:
    589 8th Ave, 18th Floor
    New York, NY 10018

LAVCA Also Has a Regional Presence in:

   Washington DC
    

    Silicon Valley:
    San Francisco, CA

Explore LAVCA.org

  • About LAVCA
  • Board, Team, & Advisors
  • Media
  • Contact Us
  • Membership Benefits
  • Members Only Access
  • Education and Programs
  • Research
  • Policy
  • LAVCA VC
  • Contact Us

@2020 - LAVCA. All Rights Reserved.


Back To Top